Acute allergic reaction and demonstration of specific IgE antibodies against α-1-protease inhibitor

European Respiratory Journal

Volumn 12, Issue 4, 1998, Pages 996-997

  Meyer, F J ^a,b   Wencker, M ^a   Teschler, H ^a   Steveling, H ^a   Sennekamp, J ^c   Costabel, U ^a   Konietzko, N ^a,d  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Lab for Allergological Invest   (Germany)

^d RUHRLANDKLINIK   (Germany)

Author keywords

1 protease inhibitor; Allergic reaction; Replacement therapy

Indexed keywords

ALPHA 1 ANTITRYPSIN; IMMUNOGLOBULIN E ANTIBODY; PROLASTIN HS; UNCLASSIFIED DRUG;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANAPHYLAXIS; ARTICLE; BRADYCARDIA; CASE REPORT; DYSPNEA; EDEMA; ENZYME REPLACEMENT; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISOELECTRIC FOCUSING; LUNG EMPHYSEMA; NAUSEA; PRICK TEST; PRIORITY JOURNAL; WHEEZING;

ADULT; ALPHA 1-ANTITRYPSIN; ANTIBODIES, ANTI-IDIOTYPIC; DRUG HYPERSENSITIVITY; EMPHYSEMA; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; INFUSIONS, INTRAVENOUS; PROTEASE INHIBITORS;

EID: 0031723072     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12040996     Document Type: Article

References (17)

1. Kueppers F, Black LF. Alpha-1-anitrypsin and its deficiency. Am Rev Respir Dis 1974; 110: 176-194.
2. Wewers MD, Casolaro MA, Sellers MA, et al. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
3. Graf HJ, Teschler R, Denker J, et al. Alpha-1-PI substitution therapy in emphysematous patients with severe alpha-1-PI deficiency: first results of the German Multicenter Study Group (WATL). Eur Respir J 1990; 3: 118S.
4. 1-antitrypsin deficiency? Eur Respir J 1997; 10: 2260-2263.
5. 1-antitrypsin. Eur Respir J 1998; 11: 428-433.
6. Coombs RRA, Gell PGH. The classification of allergic reactions underlying disease. In: Gell PGH, Coombs RRA, eds. Clinical Aspects of Immunology. Philadelphia, PA, Davis, 1963; p. 317-320.
7. Wide L, Bennich H, Johansson SGO. Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet 1967; 2: 1105-1107.
8. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, ELISA 111. Quantification of specific antibodies by enzyme labeled anti-immunoglobulin in antigen-coated tubes. J Immunol 1972; 109: 129-135.
9. Wencker M, Banik N, Konietzko N. Influence of smoking on FEV1 in patients with alpha-1-deficiency receiving augmentation therapy. Am J Respir Crit Care Med 1996; 353: A400.
10. Moser KM, Smith RM, Spragg RG, et al. Intravenous administration of alpha-1-protease inhibitor in patients of PiZ and PiM phenotype. Am J Med 1988; 84: 70-74.
11. Schmidt EW, Rasche B, Ulmer WT, et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZZ subjects with chronic obstructive lung disease. Am J Med 1988; 84: 63-69.
12. Barker AF, Buist AS, Siemsen FK, et al. One year experience with alpha-1-proteinase inhibitor in AAT deficiency syndrome. Am Rev Respir Dis 1991; 143: A672
13. Barker AF, Siemsen F, Pasley D, et al. Replacement therapy for hereditary alpha-1-antitrypsin deficiency: a program for long-term administration. Chest 1994; 105: 1406-1410.
14. Clark JA, Gross TP. Pain and cyanosis associated with alpha-1-proteinase inhibitor. Am J Med 1992; 92: 621-626.
15. Fournel MA, Newgren JO, Betancourt CM, et al. Preclinical evaluation of alpha-1-proteinase inhibitor. Pharmacokinetics and safety studies. Am J Med 1988; 84: 43-47.
16. 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
17. 1-antitrypsin for the treatment of cystic fibrosis. Chest 1996; 110: 256S-260S.